Small interfering RNA (siRNA)-based targeting breast cancer therapy Authors: Amin Talebi, Afshin Khorrami, Farshid Oruji, Shima Shabani, Saba Hajazimian, Hadi Nasiri, Soolmaz Khansalar, Alireza Isazadeh, Morteza Akbari Published: 2026 ABSTRACT AbstractBreast cancer (BC) poses a substantial impact on the global health landscape, thereby demanding the creation of novel therapeutic approaches aimed at enhancing patient outcomes. The objective of this article is to conduct an analysis of the potential benefits and drawbacks related to the application of siRNA-based therapy in the context of BC, along with its targeting capabilities. This paper commences by highlighting the imperative need for pioneering treatment methodologies in response to the substantial incidence of BC. This section of the article examines the molecular mechanisms underlying small interfering RNA (siRNA), with a particular emphasis on its role in selectively suppressing cancer-associated genes involved in tumor initiation and progression. The efficacy of therapies utilizing siRNA is reliant on the presence of effective delivery mechanisms. The objective of this research is to examine the effectiveness and safety of liposomes, nanoparticles (specifically carbon nanoparticles and metal nanoparticles), as potential vehicles for delivering targeted siRNA. Moreover, the objective of this article is to investigate the potential of siRNA in the context of mitigating drug resistance and augmenting the effectiveness of treatments. Additionally, the study aims to investigate the obstacles related to delivery efficiency, potential immune responses, and the suppression of off-target genes. The present comprehensive literature review concludes with a meticulous examination of the potential transformative effects of siRNA-based therapeutic approaches for BC. The primary objective of this study is to advance the development of enhanced and personalized therapeutic interventions for BC.Keywords: Breast cancer, siRNA, Targeted therapy, siRNA delivery Introduction Breast cancer (BC) is a prevalent global malignancy, ranking fifth in terms of cancer-related mortality. Global incidence is expected to reach 2.3 million new cases, with the fifth-most significant contribution from other cancers. Multiple studies show that BC is a complex condition influenced by various factors. Expanding therapeutic alternatives has led to improved prognosis and overall well-being [1]. Over the past century, the approach to managing BC has evolved from surgical interventions to a comprehensive treatment regimen that includes radiation, chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. The primary objective of these medical interventions is to eradicate malignant neoplasms and prolong the lifespan of individuals. However, conventional therapies are limited due to the high incidence of tumor recurrence and drug resistance [2, 3]. Cancer therapies have evolved to focus on oncogene inhibition, tumor suppressor promotion, or targeting cancerous cells through cytotoxic drugs. Oncogene dependence involves cancer cells relying on specific genes and proteins for various processes, such as proliferation, dissemination, and resistance to therapeutic interventions [4]. Monoclonal antibodies and small molecule inhibitors have been shown to impede oncoproteins’ activity, reversing malignant phenotypes [5]. However, their limited cellular uptake limits their efficacy in suppressing intracellular protein synthesis [6]. Various strategies for guiding antibodies within intracellular environments, such as nanoparticles, protein-transduction domains, and viral envelopes, have been explored, but clinical implementation remains elusive [7]. The small interfering RNA (siRNA) has been recognized as a breakthrough in RNA interference (RNAi), a crucial mechanism in gene expression regulation [8]. This paper explores the application of siRNA technology for precise modulation of cancer hallmarks in the context of BC treatment. This study offers a thorough investigation into the advantages and potential limitations linked to the application of siRNA-based approaches in the targeting of specific components of BC. The current work provides valuable insights regarding the efficacy and limitations of employing this particular strategy to enhance treatment outcomes. Molecular mechanisms of siRNA The molecular mechanism of RNAi, or selective inhibition of specific genes, has been extensively studied. The enzyme Dicer, a member of the RNase III ribonuclease family, is responsible for converting elongated double-stranded RNA molecules into siRNA molecules [9]. Its structure consists of three components: the head, the tail, and the tail. The enzymatic process of transforming double-stranded RNA (dsRNA) into siRNA is mediated by Dicer, which then connects with Argonaute 2, forming the RNA-induced silencing complex (RISC). The Argonaute protein unwinds and removes the sense or passenger strand from double-stranded siRNA, and the RISC enzyme identifies the mRNA sequence that exhibits complementarity to its own and initiates the degradation of the mRNA sequence [10]. siRNA technology has made significant progress in treating various diseases by mitigating heightened gene expression through the interaction with mRNA. This approach has the potential to overcome constraints in traditional cancer treatment using small-molecule drugs, advancing drug development techniques centered on gene functionality. Despite its specificity, siRNA therapy is limited by delivery barriers including instability, rapid clearance, and inefficient intracellular trafficking [11, 12]. siRNA-based delivery systems in BC The delivery of siRNA to tumors in living organisms faces challenges due to limited cellular uptake and a short half-life in the circulatory system. siRNA has unfavorable physicochemical properties, such as instability, negative charge, and large molecular size [13]. Its hydrophilic characteristics and physicochemical attributes hinder its efficacy in passive diffusion. Serum endonucleases degrade unbound siRNAs, leading to their rapid elimination via glomerular filtration and renal excretion [14]. The shortened half-life of siRNA is due to its rapid degradation and excretion. Nanocarriers with a diameter of 200 nm or smaller are essential for efficient delivery of siRNA to specific cells. Nanoparticles are widely recognized as safe and precise nanocarriers due to their advantageous characteristics, such as improved absorption and elimination rates, and preferential accumulation on specific targets [15]. The application of nanoparticles incorporating siRNA has demonstrated the capacity to impede the advancement of BC in controlled laboratory settings and living organisms. Nanocarriers encapsulating siRNA have shown significant effectiveness in suppressing the proliferation and metastasis of BC cells [16]. The incorporation of siRNA into nanoparticles offers a safeguard against degradation, a critical factor in BC therapy. The application of ligands to modify the surface of nanoparticles has been shown to improve targeted delivery of these nanoparticles to breast tumor sites. Ensuring the integrity and stability of siRNA is of paramount significance in BC therapy [17]. RNAi, or siRNA, has provided researchers with the ability to selectively impede protein synthesis within cellular contexts. However, the effective and optimal intracellular transportation of siRNA into neoplastic cells for gene suppression poses a significant challenge. The efficient delivery of isolated siRNAs is hindered by various limitations, including insufficient systemic stability, susceptibility to degradation by ribonucleases (RNases), and rapid renal clearance [18]. The cytotoxicity of siRNA is attributed to its capacity to elicit off-target gene silencing and deleterious alterations to genetic functionality. The consequences of exposure to siRNA depend on the activation of the innate immune response within the immune system [19]. Currently, several ongoing investigations aim to evaluate the effectiveness of encapsulating siRNA within various carrier systems’ cores [20]. Advancements in carrier systems have shown promising capabilities for the delivery of siRNA, with surface modifications capable of enduring enzymatic degradation. Nanocarriers, which have surface areas ranging from 1 to 100 nm, have been engineered to enhance the effective transportation of siRNA therapeutics to the designated site [21]. To optimize the precise targeting of BC cells, it is essential for a prospective siRNA vector to demonstrate a distinct affinity for these specific cells [22]. This can be achieved through the use of a methodology involving the design of a ligand that selectively binds to a receptor that demonstrates increased expression on the plasma membrane of BC cells [23]. Nanostructures offer several advantages compared to siRNA conjugates, such as the ability to transport a larger quantity of siRNAs during each absorption event and the incorporation of supplementary components such as homing receptors, strategies to evade endosomal pathways, therapeutic agents with synergistic effects, and imaging agents [24]. Co-administration of siRNA and anticancer therapeutics enables the precise delivery of a predetermined quantity of siRNA and anti-neoplastic bioactive compounds to a specific site, leading to a synergistic outcome [25]. Nanocarriers for efficient siRNA delivery Extensive research and technological advancements are being made to develop nanocarriers for the transportation of siRNA molecules in biomedicine. Numerous viral transmission vectors have been identified, with crucial elements like insertional mutagenesis and adverse immunogenic response being of significant importance [26]. Nanoparticles have the potential to be used for diagnostic and therapeutic applications in biomedicine. Drug delivery systems using nanocarriers utilize passive and active targeting approaches, depending on the enhanced permeability and retention (EPR) effects of permeable blood vessels [27, 28]. The advancement of tumors and the formation of blood vessels lead to a reduction in lymphatic drainage at the impacted cells. The increased vulnerability of oncogenic blood vessels enhances the ability to transport and accumulate bioactive substances as small as 400 nm onto specific tissues. Extensive research and development efforts are being focused on creating a wide range of nanostructures to efficiently deliver siRNA to BC cells. Nanoparticles can be classified into organic and inorganic categories [29]. Nanoparticles for siRNA transport Nanoparticles are small, discrete solid entities with dimensions ranging from 1 to 100 nanometers, which have been shown to improve drug absorption, distribution, metabolism, and excretion, as well as their therapeutic effects and distribution throughout the body [30]. The reticuloendothelial system (RES) recognizes particles measuring approximately 100 nm, leading to a decrease in their time in circulation and half-life. Cationic ethyl-phosphatidylcholines (ePCs) have been found to exhibit therapeutic effectiveness as transfection vectors in liposomal drug delivery systems. Nanoparticles coated with polyethylenimine (PEI) are primarily used for the delivery of siRNA [31]. A study was conducted to develop multifunctional nanoparticles that can simultaneously deliver vascular endothelial growth factor (VEGF)-siRNA and placental growth factor (PIGF)-siRNA. Polymer nanostructures were synthesized using polyethylene glycol (PEG) and mannose-modified trimethyl chitosan (TMC). The pH-responsive nanocarriers were employed for delivering siRNA molecules to M2-polarized macrophages [32]. The nanoparticles demonstrated a predilection for accumulating at tumor sites and prolonged the circulation of siRNA molecules, possibly attributable to their pH sensitivity. The application of nanoparticles enabled the intracellular accumulation of siRNA within breast tumor cells and led to a notable decrease in the expression levels of VEGF and PIGF during the treatment of BC [33]. Camorani et al. devised a novel platform using aptamers for actively delivering siRNA molecules targeting PD-L1 to BC cells [34]. The nanovectors consist of polymeric nanoparticles based on poly(lactic-co-glycolic acid) (PLGA), loaded with siRNA targeting PD-L1. The nanovectors were modified by attaching a nuclease-resistant RNA aptamer that specifically binds to TNBC cells [35]. The role of VEGF in the facilitation of BC development has been established, and the administration of glipizide, a medication, has been found to impede both the process of angiogenesis and the infiltration of tumor cells [36]. Asiatic acid has been observed to effectively inhibit the progression, angiogenesis, and proliferation of breast tumor cells by targeting the VEGF/VEGFR2 axis [37]. The primary objective of this investigation is to explore the progress made in the development of pH-responsive polymeric nanoparticles as a promising approach for the concurrent administration of paclitaxel and VEGF-siRNA in the field of BC treatment. The nanostructures displayed a particle size of 85.25 nm, a polydispersity index (PDI) of 0.26, and a zeta potential of 5.25 mV. The implementation of this therapeutic approach led to a decrease in the manifestation of VEGF [38]. In recent times, there has been a surge in the focus directed towards chitosan and other natural polysaccharides, with chitosan-based nanostructures possessing biodegradability, high safety, and bioadhesion [39]. Alginate-conjugated chitosan nanoplatforms have been utilized in current research to enhance the delivery of sphingosine-1-phosphate receptor 1 (S1PR1)-siRNA and glycoprotein 130 (GP130)-siRNA for BC therapy. The observed nanostructures exhibited inhibitory effects on the progression of BC by reducing the expression levels of S1PR1 and GP130, and demonstrated anti-neoplastic properties against colon cancer, melanoma, and breast malignancies [40]. Chitosan nanostructures face challenges in non-specific payload delivery, leading researchers to develop ligand modifications to enhance their effectiveness. Mucin 1 (MUC1), a glycoprotein, is a promising candidate for targeted therapy against tumors. Chitosan nanoparticles have been used to deliver docetaxel and insulin-like growth factor 1 (IGF-1)R-siRNA for BC treatment [41]. These nanoparticles have a size distribution ranging from 110 to 118 nm and a zeta potential falling between 12 and 14 mV. The application of nanoparticles led to increased internalization of siRNA in BC cells, resulting in a decrease in their viability. Modifying anti-MUC1 aptamers led to a reduction in IGF-1 receptor expression and downregulation of oncogenic factors, such as signal transducer and activator of transcription 3 (STAT3), Matrix Metallopeptidase (MMP)−9, and VEGF [42]. siRNA has shown effectiveness in cancer treatment and gene silencing, but its inherent negative charge hinders its ingress. However, cationic nanoparticles exhibit efficient conjugation with siRNA molecules with negative charges [43]. This study aimed to fabricate hybrid nanostructures composed of cationic lipids and polymers to facilitate the delivery of siRNA. The study found that cationic polymers, particularly PEI, exhibit notable effectiveness in facilitating the transportation of siRNA for BC treatment [44]. The influence of anionic polymers on nanostructures’ effectiveness in siRNA delivery has been studied, with previous research showing that the introduction of anionic polymers decreases their zeta potential while improving their capacity to transport cargo into cells and enhance cellular uptake capacity [45]. Carbon nanoparticles Carbon-based nanostructures, including graphene, nanotubes, and diamonds, have the potential to be manipulated for the delivery of siRNA and providing therapeutic intervention for various diseases, including cancer. These nanostructures include graphene oxide (GO), carboxylated graphene oxide (CGO), TMC, and hyaluronic acid (HA). Research has shown that ligands can significantly improve the efficacy of carbon-based nanomaterials for siRNA delivery, and they play a pivotal role in facilitating intracellular transportation of siRNA [46–49]. Previous studies have shown a potential association between hypoxia-inducible factor 1 (HIF-1) and the progression of BC. The administration of dexmetomidine leads to an increase in the expression of HIF-1 in BC cells, leading to the suppression of apoptosis [50]. The concurrent administration of HIF-1-siRNA and Dinaciclib via CGO has been found to effectively impede tumor growth by suppressing the expression of HIF-1 [51]. The incorporation of siRNA in combination therapy has exhibited a significant deceleration in the progression of BC cells, thus establishing a promising avenue for cancer treatment [52]. Modifying ligands with cell-penetrating peptides (CPPs) can improve their specificity towards BC cells [53]. Carbon nanotubes are cylindrical structures composed of carbon particles from thin graphite sheets composed of interwoven benzene rings. These nano-drug transporters exhibit an extended duration of systemic circulation, enhancing their effectiveness in penetrating cellular membranes and directly delivering their cargo into the cytoplasm of specific target tissues [54]. The chemical synthesis of single-walled nanotubes (SWNTs) can be achieved through a novel methodology, where nanotubes are generated with dimensions falling within the range of 0.80–1.20 nm in diameter and 100.0–1000.0 nm in length. When aggregated in BC cell lines, these nanotubes demonstrate a substantial inhibitory impact on the progression of cancer, resulting in a reduction of 44.0% and eliciting apoptosis in a proportion of 30% of cancerous cells [55]. In conclusion, carbon-based nanomaterials, specifically carbon nanotubes and quantum dots, have the potential to enhance the delivery of siRNA and suppress the progression of cancer. Further investigation is needed to explore the potential of these nanomaterials in the treatment of BC and other diseases. Metal nanoparticles Metal nanoparticles have been extensively investigated for delivering siRNA, similar to carbon-based nanomaterials, due to their potential safety concerns [56]. Metal nanostructures, specifically iron and silver nanoparticles, have been used in research to enhance the transportation of siRNA. Nanoplatforms have emerged as a promising approach for the simultaneous administration of siRNA and pharmaceutical agents, enabling their effective co-delivery [57, 58]. These nanoplatforms are attractive options for the therapeutic intervention of infectious diseases and cancer, as they possess the capacity to serve as carriers for siRNA within the realm of cancer therapy [59]. Superparamagnetic iron oxide nanoparticles (SPIONs) have received significant interest in cancer therapy due to their ability to serve as carriers for siRNA. They have been extensively employed in studies aimed at inhibiting BC and are considered a promising carrier in this field [60]. Studies have shown that the upregulation of HIF-1 facilitates the progression of BC cells, and the STAT3 signaling pathway plays a crucial role in the progression and development of BCs [61]. The effectiveness of SPIONs as carriers for siRNA at the nanoscale level is greatly improved when the nanoparticles are surface-modified with ligands [62]. Both targeted and non-targeted SPIONs possess the potential to be employed for the delivery of siRNA in the context of BC. However, the efficacy of gene silencing achieved through these approaches exhibits variability [63]. Gold nanoparticles (Au-NPs) are widely recognized as highly appropriate agents for bioimaging applications. The synthesis of Au-NPs involves precise control of their dimensions and configurations, and they are modified by attaching thiolated ligands to serve as carriers for genetic material. The concentration-dependent variability of Au-NPs was observed in terms of their cytotoxicity, which was accompanied by an increase in the expression of MCF-7-associated mRNA, CASP3, and P53 [64]. Silica nanoparticles (Si-NPs) are frequently employed as a targeted platform for tumor identification due to their low immunogenicity, capacity for cellular endocytosis, and enhanced efficacy in encapsulation and release kinetics [65]. Porous Si-NPs have been recognized as a noteworthy biocompatible carrier for pharmaceuticals and genetic materials. The study focused on the synthesis of mesoporous silicon nanoparticles (Si-NPs) using PEI-PEG copolymers to improve the administration of doxorubicin and P-gp siRNA. The discovery suggests that the transportation of nanoparticles has the potential to elicit a synergistic decrease in the proliferation of BC cells [66]. Comparative analysis of nanocarriers for siRNA delivery While polymeric, lipid-based, carbon, and metal nanocarriers each offer distinct advantages for siRNA delivery, their clinical translation potential varies considerably. Lipid-based nanoparticles (LNPs) are the most clinically advanced, benefiting from biocompatibility, high transfection efficiency, and an established FDA-approved formulation (Onpattro®) for hepatic siRNA delivery. However, they face challenges related to colloidal stability, rapid clearance by the RES, and dose-dependent immunogenicity [67, 68]. Polymeric nanoparticles, particularly those based on PLGA and chitosan, offer tunable physicochemical properties, sustained release, and surface modifiability [68]. Yet, concerns over polymer-associated cytotoxicity (e.g., PEI), batch-to-batch reproducibility, and complex synthesis hinder their scalability and regulatory approval. Carbon-based nanocarriers (graphene, nanotubes) exhibit ultrahigh surface area and unique optical properties, enabling multifunctionality. Nevertheless, their clinical feasibility is severely limited by poor biodegradability, potential long-term toxicity, and lack of standardized safety profiles, confining them to preclinical exploration [69, 70]. Metal nanoparticles (e.g., gold, iron oxide) provide additional functionalities such as magnetic targeting and imaging, but their non-biodegradable nature, risk of heavy metal accumulation, and immunotoxicity pose significant safety hurdles [71, 72]. From a scalability perspective, LNPs and polymeric nanoparticles (especially those using FDA-approved excipients) have established manufacturing pathways, whereas carbon and metal nanomaterials require more complex, less reproducible synthesis methods [71]. Currently, only LNP-based siRNA therapeutics have achieved clinical approval, while other platforms remain in early-phase trials or preclinical stages [73, 74]. Thus, while all carriers show promise in preclinical models, lipid-based systems currently lead the race toward clinical translation, with polymeric carriers following closely, and carbon/metal nanocarriers requiring substantial safety and manufacturing improvements. Advanced delivery strategies for siRNA in BC Recent years have witnessed significant innovation in siRNA delivery platforms beyond conventional nanoparticles. Four emerging approaches, ligand-directed delivery, stimuli-responsive systems, exosome-based carriers, and combinatorial RNA therapies, offer unprecedented opportunities for enhanced specificity, controlled release, and synergistic therapeutic effects in BC treatment. Ligand-directed active targeting strategies Ligand-directed delivery represents a paradigm shift from passive accumulation to active, receptor-mediated targeting of siRNA to BC cells. This approach leverages the overexpression of specific cell surface receptors on breast cancer cells compared to normal tissues, enabling selective uptake and reduced off-target effects [75]. Aptamer-guided systems have emerged as particularly promising due to their high specificity, low immunogenicity, and ease of chemical modification. Aptamers are single-stranded DNA or RNA molecules generated via SELEX that exhibit nanomolar-range binding affinities (Kd ∼0.5–2.5 nM) for TNBC biomarkers, including EGFR, EpCAM, nucleolin, and MUC1 [76]. Aptamer-siRNA conjugates enhance cellular uptake by 5–10-fold, improve gene silencing efficiency (80–95%), and extend siRNA stability in circulation from < 2 h to 6–9 h. In xenograft models, aptamer-siRNA therapies achieve tumor volume reductions of 60–85%, significantly outperforming non-targeted siRNA and conventional chemotherapy [76]. Peptide-directed targeting offers complementary advantages. Octreotide, a somatostatin analog, targets somatostatin receptor type 2 (SSTR2)-expressing BC cells. When combined with cell-penetrating peptides like penetratin (RK16), dual-functionalized lipid nanoparticles achieve selective delivery to HER2 + BC cells even in heterogeneous environments containing non-tumor cells [81]. These dually decorated nanoparticles enable co-delivery of siRNAs targeting both HER2 and heat shock protein 27 (Hsp27), demonstrating strong potential for combinatorial therapies [77]. Antibody and aptamer-conjugated dendrimers represent another sophisticated platform. Hyperbranched bis-MPA polyester dendrimers functionalized with MUC1 aptamers via polyethylene glycol linkers demonstrate significantly higher uptake in MCF-7 BC cells compared to non-targeted formulations. Real-time PCR confirms superior target gene inhibition, while caspase activation studies verify functional survivin silencing leading to apoptosis induction [78]. Stimuli-responsive delivery systems Stimuli-responsive or “smart” delivery systems enable spatiotemporal control over siRNA release, responding to physiological cues (pH, enzymes, reactive oxygen species) or external stimuli (light, magnetism, temperature) unique to the tumor microenvironment [30]. Multi-stimuli strategies, combining multiple triggers, offer enhanced precision. Bioorthogonal chemistry approaches enable catalyst-free reactions in physiological environments, improving therapeutic accuracy while minimizing off-target effects [79]. These systems are particularly valuable for overcoming the endosomal escape efficiency [80]. Hydrogel-based platforms provide three-dimensional networks mimicking the extracellular matrix, enabling sustained and localized siRNA delivery. Stimuli-responsive hydrogels protect RNA through physical isolation, electrostatic interactions, or complex formation, with release triggered by tumor-specific cues [79]. Despite promising preclinical results, clinical translation faces challenges including unpredictable in vivo degradation kinetics, long-term biosafety concerns, and standardization issues in personalized therapy [30]. Exosome-based nanocarriers Exosomes, endogenous nanovesicles (30–150 nm) involved in intercellular communication, have emerged as privileged siRNA delivery vehicles due to their intrinsic biocompatibility, low immunogenicity, and ability to cross biological barriers [81]. Engineered exosome platformscombine the innate targeting capabilities of exosomes with the efficient cytosolic delivery of synthetic nanoparticles. Exosome-lipid hybrid nanoparticles (ELNs) optimized through systematic formulation approaches achieve fusion efficiencies exceeding 50% and particle sizes under 170 nm while preserving exosomal markers CD9, CD63, and CD81. Cellular association studies reveal that ELNs specifically target their parental cell lines, achieving ∼2.5-fold higher siRNA association compared to conventional lipid nanoparticles [81]. Therapeutic applicationsin BC models demonstrate significant promise. ELNs delivering siRNAs targeting CD24, CD44, and CD47, immune checkpoint molecules overexpressed in triple-negative BC, enhance macrophage-mediated phagocytosis of cancer cells in vitro. In vivo studies using 4T1 and B16F10 tumor models confirm significant tumor targeting and growth inhibition, highlighting the therapeutic potential of optimized ELNs [81]. Multi-drug combination strategiesfurther expand exosome utility. Biodegradable exosome-based nanoplatforms enable co-delivery of siRNA and small molecule drugs like 3-Bromopyruvic acid (3BP). By coupling cetuximab to exosome membranes for enhanced targeting, engineered exosomes (Exo@siRNA/3BP-CTX) successfully inhibit KRAS oncogene expression while significantly reducing glucose uptake by cancer cells, promoting excessive autophagy activation and apoptosis. This approach also restores cetuximab chemosensitivity in refractory KRAS-mutant tumors, demonstrating the power of exosome-mediated combination therapy [82]. Combinatorial RNA therapies Combination strategies involving siRNA with other nucleic acid therapeutics or conventional drugs exploit synergistic mechanisms to overcome resistance and enhance efficacy [83]. siRNA-chemotherapy combinationsaddress multidrug resistance (MDR), a formidable barrier to successful cancer treatment driven by efflux pump overexpression, enhanced DNA repair, and apoptosis evasion. Nanoparticle-based co-delivery systems enable simultaneous administration of chemotherapeutic agents with siRNA targeting resistance mechanisms. Recent advances include CRISPR/Cas9 gene editing tools delivered via nanoparticles to re-sensitize resistant cancer cells, offering potential for permanent reversal of resistance mechanisms [83]. siRNA-natural product combinations leverage the synergistic anticancer effects of phytochemicals. Polyamidoamine (PAMAM) dendrimers co-delivering linc-RoR siRNA and curcumin demonstrate enhanced cytotoxicity in MCF-7 BC cells compared to individual treatments. The combination synergistically arrests the cell cycle at the G1 phase and induces apoptosis, with linc-RoR gene expression significantly downregulated. Individual treatments show lower efficacy, confirming synergism between components [84]. Dual siRNA targeting addresses multiple oncogenic pathways simultaneously. Lipid nanoparticles co-delivering siRNAs against HER2 and Hsp27 achieve enhanced cytotoxicity in HER2 + BC cells through combinatorial silencing of tumor-promoting genes. By altering targeting peptides and siRNA combinations, this platform can be adapted for diverse tumors and combination treatments [77]. Integration with immunotherapy represents an emerging frontier. Exosome-based siRNA delivery targeting LINC02544 combined with PD-1 blockade suppresses tumor growth and enhances immune cell infiltration in TNBC models, overcoming immunotherapy resistance [85]. Similarly, local siRNA delivery targeting PD-1 (pH-762) in cutaneous malignancies demonstrates complete responses in 6/16 evaluable patients, providing proof-of-concept for immune checkpoint targeting via siRNA [86]. Advanced delivery platforms Beyond conventional nanoparticle systems, several sophisticated delivery platforms have been developed that offer important technological insights for BC siRNA development, although direct clinical application in BC remains to be established [87, 88]. RONDEL (Cyclodextrin-based Polymer Nanoparticles): Developed by Calando Pharmaceuticals, this platform utilizes a four-component self-assembling system forming uniform nanoparticles of approximately 70 nm diameter. The components include: (i) a linear cyclodextrin-containing polycation (CDP) that binds siRNA through electrostatic interactions, (ii) adamantane-polyethylene glycol (AD-PEG) conjugates for steric stabilization, (iii) adamantane-PEG-transferrin (AD-PEG-Tf) conjugates for tumor targeting via transferrin receptor (TfR), and (iv) the siRNA payload [87, 89]. CALAA-01, the lead candidate targeting RRM2, was the first to demonstrate systemic siRNA delivery and RNAi-mediated mRNA knockdown in humans (melanoma patients), establishing critical proof-of-concept for receptor-mediated tumor targeting [90]. Notably, TfR is overexpressed in BC, providing a strong rationale for future applications of TfR-targeted platforms [88]. GalNAc Conjugation Technology: N-Acetylgalactosamine (GalNAc) conjugation represents the gold standard for hepatocyte-specific siRNA delivery, underpinning all seven FDA-approved siRNA therapeutics [91, 92]. The technology employs a triantennary GalNAc ligand covalently linked to siRNA, which binds the asialoglycoprotein receptor (ASGPR) on hepatocytes with high affinity (Kd ~ 2.5 nM) [93]. Although ASGPR expression is liver-specific, the platform offers critical lessons for BC: (i) multivalent ligand design principles, (ii) chemical modification strategies for enhanced stability (including anomerically stabilized linkages resistant to glycosidase degradation), and (iii) the feasibility of simple conjugate architectures that avoid complex nanoparticle formulations [93, 94]. These principles are directly applicable to developing conjugates targeting BC-associated receptors such as HER2, EGFR, or MUC1 [88]. TRIM Platform (Arrowhead Pharmaceuticals): The Targeted RNAi Molecule (TRIM) platform represents a modular ligand-siRNA conjugate system enabling extrahepatic delivery through tissue-specific targeting moieties [95]. Key technical features include algorithmic sequence selection for maximal potency, proprietary stabilization chemistry (phosphorothioate linkages and 2’-O-methyl modifications), optimized linkers maintaining conjugate stability in circulation, and high-yielding conjugation processes (75–80% yield at scales from milligram to multigram) [95]. The TRIM-BBB platform enables CNS delivery via transferrin receptor (TfR)-targeting ligands, while pulmonary TRIM targets integrin αvβ6 for lung delivery, both via subcutaneous administration [95]. For BC applications, the modular architecture, where the targeting ligand can be swapped while maintaining siRNA stabilization chemistry, provides a blueprint for developing targeted conjugates using BC-overexpressed receptors [88]. While these platforms await direct clinical validation in BC, their design principles, receptor-mediated targeting via overexpressed receptors (TfR, HER2, EGFR), chemical stabilization strategies, and modular architecture, offer critical insights for advancing BC siRNA therapeutics [88, 96]. siRNA-based BC therapy BC cells are known to evade apoptosis, a crucial mechanism involved in drug resistance development. The expression of anti-apoptotic factors, such as Bcl-2 and Bcl-xL proteins, has been found to impede the process of apoptosis in BC cells. Due to their frequent overexpression in BC and their central role in chemoresistance, Bcl-2 and Bcl-xL represent high-priority targets for siRNA-mediated silencing. The use of siRNAs that selectively target these proteins has been shown to induce programmed cell death in BC cells. The administration of a concentration of 200 nM of siRNA leads to the initiation of programmed cell death in BC cells within 72 h [97]. Survivin, a protein involved in BC cell viability, has been identified as a facilitator of BC cell proliferation, glucose assimilation, and drug resistance development. Survivin is overexpressed in the majority of BC and correlates with aggressive disease, making it an attractive target for siRNA therapy. The use of siRNA has been shown to inhibit Survivin expression, affecting both mRNA and protein levels. This has been shown to hinder the proliferation and metastasis of BC cells [98]. The transcription factor SRY-box transcription factor 18 (SOX18) plays a pivotal role in tumor progression, and inhibiting its activity impedes tumor progression, particularly in promoting angiogenesis and lymphangiogenesis, thereby facilitating metastatic dissemination. Given its role as a master regulator of metastasis and its overexpression in BC, SOX18 is a promising candidate for siRNA-based intervention. The utilization of siRNA has been shown to be highly effective in inhibiting SOX18 mRNA and protein expression in breast carcinoma cells [63]. The therapeutic targeting of the STAT6-mediated signaling pathway has shown promise in the field of BC. The activation of STAT6 at Tyrosine 641 is induced by IL-13, leading to the promotion of macrophage differentiation into an M2-polarized phenotype, which suppresses anti-tumor immunity. STAT6 also directly inhibits apoptosis in cancer cells, and its knockdown has been shown to induce cell death, justifying its selection as a therapeutic target. The downregulation of STAT6 in BC has been observed to be associated with the inhibition of programmed cell death and enhanced proliferation of cancerous cells [65]. The upregulation of E2F3 plays a pivotal role in the regulation of the cell cycle, and its expression is elevated in both BC cells and tissues. E2F3 is a key transcription factor driving proliferation and epithelial-mesenchymal transition (EMT), and its high expression correlates with poor prognosis in BC patients, making it a rational target for siRNA. The upregulation of miRNA-34a inhibits the expression of E2F3, leading to the inhibition of BC cell proliferation and the induction of apoptosis. The upregulation of E2F3 is also involved in cell proliferation, migration, and invasion in BC cells by inducing epithelial-mesenchymal transition (EMT) [99]. The application of siRNA targeting the collagen type IV alpha 2 chain (COL4A2) gene has been shown to hinder the advancement of BC cells. COL4A2 is a component of the extracellular matrix that promotes tumor cell invasion and metastasis; its silencing disrupts these processes, providing a rationale for targeting this gene. The use of reverse transcription polymerase chain reaction (RT-PCR) has confirmed the inhibitory impact of siRNA on the expression of the COL4A2 gene, resulting in a significant reduction in the proliferation and invasion abilities of breast tumor cells [100]. A discrete study utilized siRNA to target two genes associated with BC and inhibit the expression of mutant p53 and TNF, causing apoptosis and autophagy while suppressing cell proliferation. Mutant p53 is a well-established oncogenic driver in many BC types, and TNF is a pro-inflammatory cytokine that promotes tumor progression; dual targeting of these factors exploits their synergistic roles in malignancy [101]. Recent advancements in biology have helped identify new therapeutic targets for treating BC. The Forkhead box M1 (FOXM1) gene plays a significant role in the activation of the Hippo signaling pathway, which is essential for maintaining cellular stemness and promoting BC advancement. FOXM1 is a master regulator of cell cycle progression, DNA repair, and metastasis; its overexpression is an independent prognostic factor for poor survival, underscoring its value as an siRNA target. The downregulation of the FOXM1 gene has been linked to decreased proliferation of BC cells and radio-resistance in affected cells [102]. siRNA-mediated methods have shown efficacy in selectively targeting survival factors associated with BC, such as survivin, causing apoptosis and hindering the progression of breast tumors [103]. The activation of the nuclear factor-κB (NF-κB) signaling pathway has been shown to facilitate BC progression, while inhibiting NF-κB signaling can increase tumor cell vulnerability to chemotherapy [104]. NF-κB is a central mediator of inflammation, survival, and chemoresistance; its pathway components are frequently activated in BC, providing multiple nodes for siRNA intervention. The NF-κB signaling pathway has an oncogenic influence within the realm of BC [103]. An experiment used siRNA to hinder the invasion of BC cells and reduce their ability to form colonies. The suppression of IκB kinase (IKK) using siRNA hindered cellular proliferation and disrupted the G0/G1 phase of the cell cycle, mainly due to the downregulation of cyclin D1. IKK is the upstream activator of NF-κB, and its silencing effectively blocks the entire pathway, offering a strategic advantage over targeting individual downstream effectors. This suppression of NF-κB signaling and subsequent decrease in Bcl-2 expression led to apoptosis [105]. The studies provide empirical support for the effectiveness of siRNA in targeting oncogenic pathways associated with BC progression and significantly reducing the growth and infiltration of malignant cells. The targets discussed in this section were selected based on a combination of criteria: their established role as oncogenic drivers (e.g., FOXM1, STAT3), frequent overexpression in BC (e.g., Bcl-2, survivin), contribution to key malignant phenotypes such as metastasis, drug resistance, and immune evasion (e.g., SOX18, STAT6, NF-κB), and validated preclinical evidence of efficacy upon silencing. These criteria ensure that siRNA-based strategies are directed toward the most clinically relevant molecular vulnerabilities in BC (Fig. 1). Potential application of siRNA in inhibition of proliferation and metastasis of BC. The utilization siRNA has demonstrated the capacity to specifically target and suppress crucial biochemical processes implicated in the proliferation and metastasis of BC. The pathways encompass the proteins STAT3, Bcl-2, and Bcl-xL. This highlights the critical importance of utilizing siRNA as a viable approach to hinder their biological functions Targeting drug resistance factors Chemoresistance remains a major obstacle in BC treatment, often driven by the overexpression of specific genes that promote cell survival, inhibit apoptosis, or enhance drug efflux [106, 107]. As demonstrated in Fig. 2, siRNA-based strategies can target these resistance factors through distinct molecular mechanisms: Potential application of siRNA as a therapeutic strategy to combat drug resistance in individuals with cancer. Chemotherapy is the recommended therapeutic approach for cases of advanced and metastatic BC, in situations where surgical intervention is ineffective and there is a need to address resistance mechanisms. The possible mitigation of drug resistance in BC may involve the suppression of chemoresistance-associated factors, such as LINC00511, DFF45, and TMEPA1 LINC00511 functions as a competing endogenous RNA (ceRNA) that sponges tumor-suppressive miRNAs, particularly miR-29c and miR-195, leading to upregulation of anti-apoptotic proteins and enhanced cell survival during chemotherapy. siRNA-mediated silencing of LINC00511 restores miRNA activity, re-sensitizing cancer cells to apoptotic stimuli [106]. DNA fragmentation factor subunit alpha (DFF45), also known as ICAD, is a caspase-activated DNase inhibitor that blocks the final stages of apoptosis. Its overexpression in chemoresistant BC cells prevents DNA fragmentation despite caspase activation. Targeting DFF45 with siRNA removes this apoptotic block, enabling chemotherapy-induced cell death to proceed [107]. Transmembrane prostate androgen-induced protein 1 (TMEPA1) promotes resistance through multiple mechanisms: it enhances TGF-β signaling, activates NF-κB survival pathways, and upregulates ABC transporters. siRNA-mediated TMEPA1 knockdown simultaneously disrupts these resistance mechanisms, restoring chemosensitivity [106, 107]. Collectively, these examples demonstrate how siRNA can be rationally designed to target specific resistance pathways, complementing conventional chemotherapy and addressing the clinical challenge of drug-resistant BC (Fig. 2). Advantages and challenges of siRNA-based BC therapy The application of siRNA offers several advantages over anti-neoplastic medications, including its ability to disrupt post-transcriptional gene regulation without affecting chromosomal DNA, reducing the likelihood of mutation and teratogenic effects [108]. It also offers enhanced precision in the selective targeting of mRNA molecules through an RNAi mechanism, allowing for the inhibition of various cellular pathways. The primary focus of siRNA application is on impeding the proliferation of BC cells, with selective targeting of Bcl-2, Bcl-xL, Survivin, SOX18, STAT6, and STAT3 causing tumor suppression and apoptosis [109]. However, there is a gap in the current literature regarding the use of siRNA to manipulate the EMT process in BC cells [110]. Future studies may focus on inhibiting the activity of transforming growth factor (TGF-β), zinc finger E-box-binding (ZEB) proteins, and Twist, which are catalysts for the process. Additionally, siRNA has been used as a therapeutic strategy to target drug resistance and its role in BC progression [106, 107]. Nanocarriers have been used to enhance the transportation of siRNA, amplifying its inhibitory impact on breast tumor cells. Various nanoscale delivery systems, such as polymeric, lipid, carbon, and metal-based nanocarriers, have been utilized to enhance the delivery of siRNA. Lipid-based nanoparticles are preferred due to their biocompatibility. Further investigation is needed to explore the potential of siRNA and nanoplatforms incorporating siRNA in cancer treatment [111]. The administration of siRNA can lead to unintended consequences or toxicity, with limitations such as reduced tissue penetration, ambiguity, inadequate internalization, and non-specific immune response. However, siRNAs are highly selective in inhibiting oncogene overexpression in the cytoplasm and have been observed to elicit recognition by innate immune system receptors, particularly Toll-like receptors (TLRs). To assess siRNA toxicity, comprehensive investigations and preclinical research are crucial [112]. The use of nanoparticles in drug delivery faces challenges such as negative charges on cell surfaces, suboptimal pharmacokinetic properties, susceptibility to immune regulation, and rapid elimination from the bloodstream due to liver sequestration and glomerular filtration. Modified ribosomal ring and nuclear bases have been observed to enhance siRNA stability, leading to a significant decrease in immune responses and reduced off-target effects [113]. siRNAs have been observed in phagocytes of the RES, and approaches to reduce non-specific interaction with phagocytes include PEGylation and functionalization of nanocomposite surfaces. The small size of siRNAs compared to renal filtration thresholds makes them efficiently eliminated from the organism through renal filtration [114]. RNAi therapy has shown significant efficacy in managing various medical conditions, but challenges remain in clinical contexts due to its stability and vulnerability to enzymatic degradation. The bioactive properties of siRNA remain quiescent until successful entry into the intracellular cytoplasm. The transportation of siRNA molecules across cellular boundaries is impeded by various obstacles, such as the internalization of accumulated siRNA within endosomes and the stimulation of the innate immune system in cellular processes. Overcoming these limitations poses a significant challenge in the field of siRNA therapy. Despite promising preclinical results, the clinical translation of siRNA-based therapies for BC faces several critical barriers: First, physiological barriers in humans, including dense tumor stroma, heterogeneous vascularization, and elevated interstitial fluid pressure, significantly impede nanoparticle penetration and siRNA accumulation, unlike in simplified preclinical models. Second, targeted delivery remains inefficient due to rapid clearance by the RES and insufficient tumor-specific homing, resulting in suboptimal siRNA concentrations at metastatic sites [115, 116]. Third, endosomal entrapment is a major bottleneck; less than 1–2% of internalized siRNA escapes into the cytoplasm, with the majority undergoing lysosomal degradation before reaching the RNAi machinery. Fourth, immunostimulatory effects, activation of TLRs triggering inflammatory cytokine responses, raise safety concerns, despite chemical modifications to reduce immunogenicity [117, 118]. Finally, BC heterogeneity across subtypes (luminal, HER2-enriched, triple-negative) and intratumoral variability limit the universal applicability of single-target approaches, contributing to variable responses and potential resistance. These interconnected barriers, physiological, immunological, and biological, explain the gap between preclinical promise and clinical reality, emphasizing the need for next-generation delivery systems addressing tumor penetration, endosomal escape, and targeting specificity in the context of human disease complexity [115, 119]. Critical evaluation of safety challenges in clinical translation While siRNA-based therapies offer unprecedented specificity in gene silencing, their clinical translation is constrained by three interconnected safety challenges that require rigorous evaluation: off-target effects, immunogenicity, and long-term toxicity of both siRNA and nanocarriers [67]. Off-target effectsrepresent a fundamental safety concern arising from partial sequence complementarity between siRNA and unintended mRNAs. These effects can be hybridization-dependent, where siRNAs silence genes with partial homology to the target sequence, or hybridization-independent, involving saturation of the RNAi machinery and microRNA competition [120]. Notably, even FDA-approved siRNA therapeutics have demonstrated off-target activities in preclinical models, though chemical modifications, particularly 2’-O-methyl modifications of the guide strand and emerging modifications such as α-(l)-threofuranosyl nucleic acid (TNA), have substantially mitigated this risk by decreasing thermodynamic binding affinity to non-target sequences [121, 122]. However, current regulatory frameworks, while evolving with recent FDA guidance documents, still present challenges in standardizing systematic off-target assessment methodologies [123]. Immunostimulatory effectspose a second critical barrier. Synthetic siRNAs can activate innate immune receptors, including endosomal TLRs (TLR3, TLR7, TLR8) and cytoplasmic sensors (RIG-I, MDA5), triggering inflammatory cytokine cascades through both MyD88-dependent and -independent pathways [117, 124]. This response can manifest clinically as complement activation-related pseudoallergy (CARPA), characterized by infusion reactions, cytokine release syndrome, and in severe cases, anaphylaxis [120]. While PEGylation of nanoparticles reduces immune recognition and prolongs circulation, it paradoxically introduces new risks: anti-PEG antibodies, present in up to 70% of untreated individuals due to widespread PEG-containing consumer products, can accelerate clearance and trigger hypersensitivity reactions upon repeat dosing through the accelerated blood clearance (ABC) phenomenon [125]. Advanced chemical modification strategies and biomimetic coatings have been developed, but complete immune evasion remains elusive [117]. Long-term toxicity considerations differ fundamentally between siRNA and its delivery vehicles. Chemically modified siRNAs themselves have shown favorable safety profiles in chronic dosing regimens, with approved drugs like patisiran demonstrating durable safety over years of administration [120, 121]. However, nanocarriers, particularly non-biodegradable platforms, raise concerns about tissue accumulation and chronic toxicity. Carbon-based nanomaterials and metal nanoparticles persist in reticuloendothelial organs, with unclear long-term consequences regarding bioaccumulation, trophic transfer, and potential biomagnification. Even biodegradable carriers like lipid nanoparticles can induce transient liver enzyme elevations and infusion-related reactions, though these are typically manageable [67]. From a regulatory perspective, the field has achieved remarkable progress: seven siRNA therapeutics have received FDA approval to date, predominantly using GalNAc conjugation for hepatocyte targeting or lipid nanoparticle formulations. Recent FDA guidance on oligonucleotide therapeutics recommends a comprehensive nonclinical safety assessment, including evaluation of exaggerated pharmacology effects, off-target hybridization-dependent and -independent effects, and immunogenicity risk assessment. However, extrapolating these safety data to novel formulations, particularly for extrahepatic delivery or non-biodegradable nanomaterials, requires caution, as each platform exhibits unique toxicity signatures that demand individualized preclinical evaluation [67, 120]. Clinical landscape of siRNA-based therapies in BC While the therapeutic potential of siRNA in BC has been extensively validated in preclinical models, clinical translation remains in early stages. To date, no siRNA therapeutic has received FDA approval specifically for the BC indication. However, several ongoing and completed clinical trials provide critical insights into the feasibility, safety, and efficacy of this approach. TTX-MC138 represents the most advanced siRNA-based candidate specifically developed for metastatic BC. This first-in-class therapeutic utilizes aminated dextran-coated iron oxide nanoparticles to deliver locked nucleic acid (LNA)-based antagomirs targeting miR-10b, identified as a master regulator of metastatic tumor cell viability [126]. A Phase 0 microdosing trial (IND163800) demonstrated selective accumulation of the drug in bone, lung, and liver metastases, with tumor-to-blood ratios indicating preferential retention. Remarkably, even at a 100 µg microdose, robust pharmacodynamic activity was observed, with 70% inhibition of the miR-10b target sustained throughout the study period [127]. Subsequently, a Phase 1a dose-escalation trial has treated 13 patients across four dose levels (0.8–4.8 mg/kg), with no dose-limiting toxicities reported to date. Two patients have maintained stable disease for approximately seven months, receiving seven doses of TTX-MC138, and pharmacodynamic analysis at 24 h post-dosing confirms miR-10b target engagement in 5 out of 6 patients analyzed [127]. This proof-of-concept study establishes that tumor-targeted nucleic acid therapeutics can achieve clinically meaningful target engagement with a favorable safety profile. Several programs are advancing through preclinical development toward clinical entry. Exosome-based siRNA delivery targeting LINC02544 has demonstrated efficacy in overcoming immunotherapy resistance in triple-negative BC models. Studies by Lian et al. showed that LINC02544 is significantly overexpressed in TNBC and regulates immune resistance through the miR-497-5p/CAPRIN1 axis [85]. Exosome-mediated siRNA delivery targeting LINC02544 (exo/si-LINC02544) combined with PD-1 blockade suppressed tumor growth and enhanced immune cell infiltration in murine TNBC models, providing a promising strategy to overcome immunotherapy resistance [85]. Regulatory considerations for BC siRNA therapeutics continue to evolve. Recent FDA guidance (June 2024) on oligonucleotide therapeutics emphasizes the importance of comprehensive clinical pharmacology evaluations, including assessment of QTc prolongation potential, immunogenicity risk, impact of hepatic and renal impairment, and drug-drug interactions. Additionally, draft guidance on nonclinical safety assessment (November 2024) recommends evaluating exaggerated pharmacology effects, off-target hybridization-dependent and -independent effects, and immunogenicity risk. The successful navigation of these regulatory pathways by programs like TTX-MC138 provides a roadmap for future BC siRNA candidates. Notably, the use of Phase 0 microdosing studies, as exemplified by TTX-MC138, offers an efficient strategy to obtain critical human pharmacokinetic and pharmacodynamic data while minimizing patient risk and development costs [127]. In summary, while no siRNA therapeutic has yet received regulatory approval for BC, the clinical pipeline is maturing. The demonstration of target engagement, tumor-selective delivery, and manageable safety profiles in early-phase trials provides optimism that siRNA-based approaches may eventually fulfill their promise in BC treatment. Conclusion This article presents a thorough examination of the benefits and drawbacks related to siRNA-based therapy in the context of BC, with a specific emphasis on its potential as a therapeutic approach. The global impact of BC highlights the need for innovative therapeutic approaches. The utilization of siRNA-based therapy has emerged as a promising approach to accomplish this goal. The application of siRNA in targeted gene suppression shows potential in inhibiting the progression and replication of cancer cells, thereby improving patient prognosis. Liposomes and nanoparticles have been found to possess the ability to enhance the delivery of siRNA and enhance therapeutic efficacy. Furthermore, the incorporation of individualized therapeutic methodologies that incorporate the application of siRNA to selectively target specific genes represents an innovative approach in the treatment of BC. The issue of drug resistance presents a substantial obstacle within the realm of cancer therapy, specifically in the context of BC. Nevertheless, the implementation of siRNA-based methodologies demonstrates promise in enhancing the efficacy of therapeutic interventions targeted towards addressing this particular ailment. To enhance the therapeutic effectiveness of siRNA-based therapies, it is crucial to take into account critical factors, including delivery efficiency, potential immune reactions, and the inhibition of off-target gene expression. All in all, the application of siRNA-based therapy in the context of BC targeting represents a significant advancement in the realm of cancer treatment. To optimize BC management and improve patient outcomes, it is crucial to maintain continuous research and optimization efforts. This will allow for the effective utilization of inherent advantages and the adoption of more efficient and personalized interventions with the potential to transform the field. Acknowledgements Not applicable. Author contributions Amin Talebi, Afshin Khorrami, Farshid Oruji, Shima Shabani, Saba Hajazimian: Data curation, Writing - original draft. Hadi Nasiri, Alireza Isazadeh, Soolmaz Khansalar: Writing - review & editing, Investigation. Morteza Akbari: Writing - review & editing, Supervision, Project administration. Funding Not applicable. Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.